HC Wainwright Comments on Surrozen FY2030 Earnings

Surrozen, Inc. (NASDAQ:SRZN) – HC Wainwright issued their FY2030 earnings per share estimates for shares of Surrozen in a report issued on Tuesday, March 24th. HC Wainwright analyst M. Caufield forecasts that the company will post earnings of ($3.54) per share for the year. HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($8.49) per share.

Several other research firms have also recently commented on SRZN. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price target on shares of Surrozen in a research note on Tuesday. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Surrozen Trading Up 7.1%

Shares of SRZN stock opened at $28.00 on Wednesday. The company has a market capitalization of $239.96 million, a P/E ratio of -0.84 and a beta of 0.53. The business’s 50 day moving average is $24.50 and its two-hundred day moving average is $18.87. Surrozen has a twelve month low of $5.90 and a twelve month high of $29.59.

Surrozen (NASDAQ:SRZN) last posted its quarterly earnings data on Monday, March 23rd. The company reported ($7.59) EPS for the quarter, missing the consensus estimate of ($1.29) by ($6.30). Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%. The company had revenue of $0.53 million for the quarter, compared to analysts’ expectations of $0.66 million.

Insiders Place Their Bets

In related news, major shareholder Group Gp Lp Column III bought 18,052 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was bought at an average cost of $19.60 per share, with a total value of $353,819.20. Following the completion of the acquisition, the insider owned 1,016,658 shares in the company, valued at approximately $19,926,496.80. This represents a 1.81% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Tim Kutzkey purchased 18,052 shares of Surrozen stock in a transaction dated Tuesday, January 20th. The shares were bought at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the transaction, the director owned 1,016,658 shares in the company, valued at approximately $19,926,496.80. This trade represents a 1.81% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 330,291 shares of company stock worth $7,478,785. 45.18% of the stock is owned by company insiders.

Hedge Funds Weigh In On Surrozen

Hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its position in Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in Surrozen in the fourth quarter valued at $99,000. Citadel Advisors LLC grew its holdings in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Surrozen in the fourth quarter valued at $247,000. Finally, Geode Capital Management LLC increased its position in shares of Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares in the last quarter. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen News Summary

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buys by major shareholder TCG Crossover GP II — the fund bought 106,658 shares on March 24 (~$24.69 avg) and has repeatedly purchased stock in March, signaling strong insider conviction that can support the share price. SEC Filing
• Positive Sentiment: Additional TCG purchase: 15,223 shares on March 23 (~$24.90 avg), a follow-on buy that reinforces the insider buying narrative. InsiderTrades article
• Positive Sentiment: HC Wainwright reiterated a “Buy”, raised multi-quarter and multi-year EPS projections (less negative) and set a $36 price target — a constructive analyst view that can attract demand. Article
• Positive Sentiment: Cantor Fitzgerald assigned an “Overweight” rating with a higher price target (reported this week), providing another institutional buy-side signal. Article
• Neutral Sentiment: Institutional ownership is high (many hedge funds hold SRZN) and several institutions increased positions in recent quarters — supportive for liquidity but not an immediate catalyst.
• Negative Sentiment: Lifesci Capital cut multiple near-term EPS estimates (Q1–Q4 2026 and FY2026), making its outlook more pessimistic and creating downside pressure for sentiment. MarketBeat coverage
• Negative Sentiment: Recent quarterly results (reported March 23) were a significant miss (EPS deeply negative vs. expectations) and the company remains loss-making with volatile margins — a fundamental risk that keeps shares speculative despite positive headlines. Earnings detail

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.